← Leaderboards
Kevin J Yarema
Johns Hopkins University
$6,625,563
Attributed
$8,452,159
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,452,159 · 5
By mechanism
R01$7,654,395 · 3
R21$797,764 · 2
Top collaborators
- Jennifer Hartt Elisseeff5 shared
- Frederick J Krambeck5 shared
- Jamie Berta Spangler2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Pamela L. Zeitlin$9,680,949
- Noel T Mueller$3,622,827
- George J Dover$7,479,087
- Jennifer Lynn Bizon$9,186,341
- Michela Gallagher$29,291,902
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsBaseAnalogSugarMolecularDesignMetabolicSialic AcidsPathway InteractionsPolysaccharidesTranslationsResponseLaboratoriesBiochemicalCell LineSignal TransductionGrowthGlycosylationMalignant NeoplasmsIn VivoProteinsScaffoldLinkCell Surface
Grant awards (29)
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$343,015
R01 · FY2022 · CA · contact PI
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$350,016
R01 · FY2021 · CA · contact PI
OPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERING$187,064
R21 · FY2021 · CA · contact PI
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$350,016
R01 · FY2020 · CA · contact PI
OPTIMIZING THE PRE-CLINICAL DEVELOPMENT OF IMMUNOTHERAPEUTIC ANTIBODIES THROUGH GLYCOENGINEERING$223,115
R21 · FY2020 · CA · contact PI
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$339,515
R01 · FY2019 · CA · contact PI
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$349,749
R01 · FY2018 · CA · contact PI
AGX1/2 inhibitors as key modulators of the hexosamine biosynthetic pathway$176,175
R21 · FY2016 · CA · contact PI
AGX1/2 inhibitors as key modulators of the hexosamine biosynthetic pathway$211,410
R21 · FY2015 · CA · contact PI
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$297,635
R01 · FY2014 · CA · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$446,662
R01 · FY2013 · AR
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$288,413
R01 · FY2013 · CA · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$407,271
R01 · FY2012 · AR
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$306,834
R01 · FY2012 · CA · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$51,893
R01 · FY2012 · AR
Glucosamine and Novel Anolgs for Cartilage Regeneration$407,271
R01 · FY2011 · AR
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$306,824
R01 · FY2011 · CA · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$413,881
R01 · FY2010 · AR
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and$355,630
R01 · FY2010 · EB · contact PI
Mechanism and Anti-Cancer Activity of SCFA-Hexosamine Analogs$316,330
R01 · FY2010 · CA · contact PI
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and$359,494
R01 · FY2009 · EB · contact PI
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and$21,641
R01 · FY2009 · EB · contact PI
Monosaccharide Analogs, Sialic Acid Metabolism and Apoptosis$21,641
R01 · FY2009 · CA · contact PI
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and$359,757
R01 · FY2008 · EB · contact PI
Monosaccharide Analogs, Sialic Acid Metabolism and Apoptosis$302,623
R01 · FY2008 · CA · contact PI
Engineering a Carbohydrate-Biomaterial Interface for Control of Wnt Signaling and$324,531
R01 · FY2007 · EB · contact PI
Monosaccharide Analogs, Sialic Acid Metabolism and Apoptosis$302,754
R01 · FY2007 · CA · contact PI
Probing the Connections between Monosaccharide Analogs, Sialic Acid Metabolism, a$311,152
R01 · FY2006 · CA · contact PI
Monosaccharide Analog/Sialic acid Metabolism &Apoptosis$319,847
R01 · FY2005 · CA